The DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.
A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine
Abstract
Background A previous pilot study of open-label mirtazapine augmentation conducted by the authors in 20 depressed patients yielded a 55% response rate at week 4. A double-blind controlled trial was undertaken to further elucidate the efficacy of this intervention. Methods 26 adult outpatients with persistent major depression despite adequate antidepressant monotherapy were randomized to receive 4 weeks of mirtazapine or placebo augmentation. Mirtazapine was begun at 15 mg at bedtime, with possible titration to 30 mg at bedtime per physician's discretion after week 1. Results Categorical positive response rate at end point was 64% for active drug and 20% for placebo. Remission rates were 45.4% and 13.3% for active drug and placebo groups, respectively, Mirtazapine demonstrated statistically significant superiority to placebo on most major outcome measures, and was associated with improvement in overall functioning and quality of life. There were no significant group differences with regard to emergent side effects, weight change, or serum concentrations of primary antidepressants. Conclusions Mirtazapine appears safe and effective for short-term antidepressant augmentation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two studies (Barbosa et al., 2003; Carpenter et al., 2002) had included patients with MDD (n=38) and bipolar-II disorder (n=11), without providing separate outcomes for MDD patients.”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Carpenter et al., 2002
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
(1976) · Medical Entomology and Zoology · Cited by 8,899
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959
(1993) · PubMed · Cited by 1,900
Quality of Life Enjoyment and Satisfaction Questionnaire
Endicott, J., Nee, J., Harrison, W., & Blumenthal, R. (2016) · PsycTESTS Dataset · doi:10.1037/t49981-000 · Cited by 188
Wheatley, D. P., Moffaert, M. V., Timmerman, L., & Kremer, C. M. E. (1998) · PubMed · Cited by 157
Wheatley, D. P., van Moffaert, M., Timmerman, L., Kremer, C. M. E., & The Mirtazapine-Fluoxetine Study Group (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0606 · Cited by 145
Haddjeri, N., Blier, P., & de Montigny, C. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199512004-00003 · Cited by 137
Cited by
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Kennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525
Metadata
- Authors
- Carpenter, L. L., Yasmin, S., & Price, L. H.
- Affiliations
- Brown University (US)
- Corresponding author
- Carpenter, Linda L
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2002-01
- Volume
- 51
- Issue
- 2
- Pages
- 183-188
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W1979281142
- Cited by
- 244
- References
- 20
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 9 · 2021: 6 · 2020: 7 · 2019: 9 · 2018: 3 · 2017: 6 · 2016: 12 · 2015: 17 · 2014: 10 · 2013: 10 · 2012: 15
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- mirtazapine, antidepressant augmentation, major depressive disorder, treatment-resistant depression, antidepressant monotherapy, remission, quality of life, drug safety, adverse effects
- MeSH terms
- Mirtazapine, Adult, Antidepressive Agents, Antidepressive Agents, Tricyclic, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Drug Synergism, Drug Therapy, Combination, Female, Humans, Male, Mianserin, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine. https://app.cochat.ai/papers/10.1016/s0006-3223(01)01262-8
- The paper
- Carpenter, L. L., Yasmin, S., & Price, L. H. (2002). A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine. Biological Psychiatry. https://doi.org/10.1016/s0006-3223(01)01262-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.